FBIOP Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $137,000.00
Insider Selling (Last 12 Months): $0.00

Fortress Biotech Insider Trading History Chart

This chart shows the insider buying and selling history at Fortress Biotech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fortress Biotech Share Price & Price History

Current Price: $19.80
Price Change: Price Decrease of -0.29 (-1.44%)
As of 02/6/2023 01:00 AM ET

This chart shows the closing price history over time for FBIOP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
[Full Story]

Fortress Biotech Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/1/2022Lindsay A Md RosenwaldCEOBuy100,000$0.68$68,000.0011,730,324View SEC Filing Icon  
10/21/2022Lindsay A Md RosenwaldCEOBuy100,000$0.69$69,000.0011,625,324View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Fortress Biotech (NASDAQ:FBIOP)

Fortress Biotech Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
10/25/2022Shikiar Asset Management Inc.62,000$1.16M0.5%-17.3%0.000%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Fortress Biotech logo
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Read More on Fortress Biotech

Today's Range

Now: $19.80
Low: $19.80
High: $20.35

50 Day Range

MA: $19.24
Low: $17.55
High: $20.64

52 Week Range

Now: $19.80
Low: $16.86
High: $26.00


15,568 shs

Average Volume

13,995 shs

Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Fortress Biotech?

Fortress Biotech's top insider investors include:
  1. Lindsay A Md Rosenwald (CEO)
Learn More about top insider investors at Fortress Biotech.